Type I IFN protects against murine lupus

Area of Science:

• Immunology
• Rheumatology
• Molecular Biology

Background:

• Type I (IFN-alpha/beta) and type II (IFN-gamma) interferons are implicated in systemic lupus erythematosus (SLE) pathogenesis.
• The specific roles of type I and type II IFN signaling pathways in SLE require further elucidation.

Purpose of the Study:

• To investigate the distinct roles of type I and type II IFN signaling in the development of lupus autoimmunity.
• To determine the impact of lacking type I IFN receptor (IFN-RI) or type II IFN receptor (IFN-RII) on SLE progression in MRL/lpr mice.

Main Methods:

• Generation of congenic lupus-prone MRL/CD95(lpr/lpr) mice deficient in IFN-RI, IFN-RII, or both.
• Assessment of autoimmune phenotypes including lymphadenopathy, autoantibody production, and renal disease.
• Evaluation of B cell activation in response to type I IFN.

Main Results:

• IFN-RII deficiency protected MRL/lpr mice from key autoimmune manifestations.
• IFN-RI deficiency unexpectedly exacerbated lymphoproliferation, autoantibody production, and end-organ damage.
• Mice lacking both receptors showed an intermediate phenotype, with type I IFNs demonstrating a suppressive effect on MRL B cell activation.

Conclusions:

• Type I IFNs exert a protective role against the humoral and end-organ autoimmune syndromes in MRL/lpr mice, independent of IFN-gamma.
• Findings suggest caution regarding the use of type I IFN antagonists in treating autoimmune diseases.
• Further research is needed on the interplay between type I and type II IFNs in pathogenic autoantibody development.